...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!
Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials
Due Dilligence
Epigenetic Therapeutic Targets Summit, 7/15/2021: Clinical Development of the BET Bromodomain Inhibitor ZEN-3694
Posted by:
BearDownAZ
on
Jul 22, 2021 09:56AM
Triple Negative Breast Cancer Drug Development Digital Summit 4/29/2021
Posted by:
BearDownAZ
on
Jun 24, 2021 04:13PM
Zenith Epigenetics Links
Awaken Dormant DNA, Epigenetically
Article in "Genetic Engineering & Biotechnology News" with a large focus on Resverlogix and Zenith
Posted by:
BearDownAZ
on
Sep 01, 2016 09:27AM
NYAS Epigenetics: Cancer and Beyond
That link will take you to the overview of the eBriefing of this 4/28/2016 symposium. If you click on the "Media" you will see the slides and audio that have been made available. Included are the talks from Resverlogix, given by Ewelina Kulikowski and from Zenith Epigenetics, given by Eric Campeau.
Posted by:
BearDownAZ
on
Jul 07, 2016 07:39PM
RVX-297- a novel BD2 selective inhibitor of BET bromodomains
Posted by:
BearDownAZ
on
Jun 13, 2016 04:29PM
Zenith AGM January 7, 2016 (transcript posted by Masila)
Posted by:
BearDownAZ
on
Mar 14, 2016 04:29PM